REGN
Income statement / Annual
Last year (2024), Regeneron Pharmaceuticals, Inc.'s total revenue was $14.20 B,
an increase of 8.27% from the previous year.
In 2024, Regeneron Pharmaceuticals, Inc.'s net income was $4.41 B.
See Regeneron Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$14.20 B |
$13.12 B |
$12.17 B |
$16.07 B |
$8.50 B |
$7.86 B |
$6.71 B |
$5.87 B |
$4.86 B |
$4.10 B |
| Cost of Revenue |
$1.97 B
|
$1.82 B
|
$1.56 B
|
$2.44 B
|
$1.12 B
|
$782.20 M
|
$434.10 M
|
$397.06 M
|
$299.69 M
|
$392.71 M
|
| Gross Profit |
$12.23 B
|
$11.30 B
|
$10.61 B
|
$13.63 B
|
$7.38 B
|
$7.08 B
|
$6.28 B
|
$5.48 B
|
$4.56 B
|
$3.71 B
|
| Gross Profit Ratio |
0.86
|
0.86
|
0.87
|
0.85
|
0.87
|
0.9
|
0.94
|
0.93
|
0.94
|
0.9
|
| Research and Development Expenses |
$5.13 B
|
$4.44 B
|
$3.59 B
|
$2.91 B
|
$2.74 B
|
$3.04 B
|
$2.19 B
|
$2.08 B
|
$2.05 B
|
$1.62 B
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.56 B
|
$1.32 B
|
$1.18 B
|
$838.53 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$2.95 B
|
$2.63 B
|
$2.12 B
|
$1.82 B
|
$1.35 B
|
$1.83 B
|
$1.56 B
|
$1.32 B
|
$1.18 B
|
$838.53 M
|
| Other Expenses |
$154.40 M
|
$0.00
|
-$89.90 M
|
-$45.60 M
|
-$280.40 M
|
$219.30 M
|
$19.10 M
|
-$1.08 M
|
-$926,000.00
|
$0.00
|
| Operating Expenses |
$8.24 B
|
$7.25 B
|
$5.62 B
|
$4.69 B
|
$3.80 B
|
$4.87 B
|
$3.74 B
|
$3.40 B
|
$3.23 B
|
$2.46 B
|
| Cost And Expenses |
$10.21 B
|
$9.07 B
|
$7.18 B
|
$7.12 B
|
$4.92 B
|
$5.65 B
|
$4.18 B
|
$3.79 B
|
$3.53 B
|
$2.85 B
|
| Interest Income |
$711.40 M
|
$495.90 M
|
$160.10 M
|
$45.80 M
|
$18.50 M
|
$30.20 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$55.20 M
|
$73.00 M
|
$59.40 M
|
$57.30 M
|
$56.90 M
|
$30.20 M
|
$28.20 M
|
$25.12 M
|
$7.20 M
|
$14.24 M
|
| Depreciation & Amortization |
$482.90 M
|
$421.00 M
|
$341.40 M
|
$286.20 M
|
$235.90 M
|
$210.30 M
|
$148.20 M
|
$145.47 M
|
$104.75 M
|
$74.91 M
|
| EBITDA |
$5.32 B |
$4.69 B |
$5.34 B |
$9.28 B |
$3.90 B |
$2.42 B |
$2.68 B |
$2.08 B |
$1.44 B |
$1.33 B |
| EBITDA Ratio |
0.37
|
0.36
|
0.42
|
0.58
|
0.46
|
0.28
|
0.38
|
0.35
|
0.27
|
0.31
|
| Operating Income Ratio |
0.28
|
0.31
|
0.39
|
0.56
|
0.42
|
0.28
|
0.38
|
0.35
|
0.27
|
0.31
|
| Total Other Income/Expenses Net |
$789.20 M
|
$152.20 M
|
$119.90 M
|
$379.00 M
|
$233.80 M
|
$219.30 M
|
$19.10 M
|
-$1.08 M
|
-$926,000.00
|
-$26.82 M
|
| Income Before Tax |
$4.78 B
|
$4.20 B
|
$4.86 B
|
$9.33 B
|
$3.81 B
|
$2.43 B
|
$2.55 B
|
$2.08 B
|
$1.33 B
|
$1.23 B
|
| Income Before Tax Ratio |
0.34
|
0.32
|
0.4
|
0.58
|
0.45
|
0.31
|
0.38
|
0.35
|
0.27
|
0.3
|
| Income Tax Expense |
$367.30 M
|
$245.70 M
|
$520.40 M
|
$1.25 B
|
$297.20 M
|
$313.30 M
|
$109.10 M
|
$880.00 M
|
$434.29 M
|
$589.04 M
|
| Net Income |
$4.41 B
|
$3.95 B
|
$4.34 B
|
$8.08 B
|
$3.51 B
|
$2.12 B
|
$2.44 B
|
$1.20 B
|
$895.52 M
|
$636.06 M
|
| Net Income Ratio |
0.31
|
0.3
|
0.36
|
0.5
|
0.41
|
0.27
|
0.36
|
0.2
|
0.18
|
0.15
|
| EPS |
40.9 |
37.05 |
40.51 |
76.4 |
32.65 |
19.38 |
21.29 |
11.27 |
8.55 |
6.17 |
| EPS Diluted |
38.34 |
34.77 |
38.22 |
71.97 |
30.52 |
18.46 |
21.29 |
10.34 |
7.7 |
5.52 |
| Weighted Average Shares Out |
$107.90 M
|
$106.70 M
|
$107.10 M
|
$105.70 M
|
$107.60 M
|
$109.20 M
|
$114.80 M
|
$115.90 M
|
$116.25 M
|
$115.23 M
|
| Weighted Average Shares Out Diluted |
$115.10 M
|
$113.70 M
|
$113.50 M
|
$112.20 M
|
$115.10 M
|
$114.60 M
|
$114.80 M
|
$115.91 M
|
$116.30 M
|
$115.23 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
